MAPT and behavioral variant of frontotemporal dementia: The heterogeneity of the bvFTD group must also be considered, particularly in terms of (i) variable reaction times during the Go trials, although our analyses compared Go with NoGo trials to ameliorate the effects of variability in responding; (ii) variable pathology, with a likely mixture of tau and TDP43 pathologies in the group; and (iii) concurrent drug treatment that may differentially affect neuronal responses.